Login to Your Account



Pharmion, MethylGene Team For $100M Cancer Partnership

By Donna Young


Tuesday, August 21, 2007
In a new joint research venture worth up to $100 million, MethylGene Inc. and Pharmion are developing novel small-molecule inhibitors targeting sirtuins, a distinct member of the histone deacetylase enzyme class implicated in cell survival and death. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription